工業技術研究院

技術簡介

配位超分子複合載體技術能大幅提升藥物水溶性並且克服了眼藥水無法對眼後房組織給藥的困難，使眼藥水能將藥物遞送至眼後房的視網膜及脈絡膜。目前已有產品運用此技術於治療濕式黃斑部眼藥水產品開發，目前已進入臨床二期階段。

Abstract

The coordination supramolecular complex carrier technology can largely enhance the water solubility of hydrophobic drug and overcome the challenge of drug delivery to the posterior ocular segments through topical administration of eye drop products, enabling drug transport from the ocular surface to the retina and choroid. This technology has been utilized in the development of an eye drop product for the treatment of wet age-related macular degeneration, which has already entered phase 2 clinical trials.

技術規格

應用此技術的眼滴劑產品經：1. 藥物C14修飾於大鼠眼球驗證藥物有效傳遞至眼底。2. 於兔子及猴子驗證脈絡膜及視網膜曝藥皆至少高於藥物IC50的100倍。3. 於猴子藥效驗證，眼滴劑給藥療效與眼內注射臨床一線用藥Eylea相當。

Technical Specification

The eye drop product utilizing this technology has undergone the following validations: 1. the radiographic study confirmed that the 14C-labeled drug can reach the posterior ocular tissues through the eye drop administration. 2. Drug exposure on retina and choroid was at least 100-fold higher than the drug’s IC50 in rabbit and monkey ocular pharmacokinetic studies. 3. A comparible therapeutic efficacy of the eye drop product was observed as compared to intravitreal injection of Eylea in in a non-human primate pharmacodynamic study.

技術特色

配位超分子複合載體技術能大幅提升藥物水溶性並且克服了眼藥水無法對眼後房組織給藥的困難，使眼藥水能將藥物遞送至眼後房的視網膜及脈絡膜。目前已有產品運用此技術於治療濕式黃斑部眼藥水產品開發，目前已進入臨床二期階段。

應用範圍

病灶位於眼後房組織之疾病，如黃斑部病變、糖尿病或高度近視引發的視網膜病變、后葡萄球膜炎等疾病

接受技術者具備基礎建議（設備）

生物、化學實驗室

接受技術者具備基礎建議（專業）

生技製藥

聯絡資訊